PBLS vs PSNL: fair value comparison
Parabilis Medicines, Inc. and Personalis, Inc. · Updated 2026-10-19
PBLS has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. PSNL has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, PBLS currently ranks higher by quality score.
| PBLS | PSNL | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $22.75 | $15.65 |
| 12-month range | $22.75–$39.47 | $5.04–$18.38 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #192 of 301 Healthcare | #193 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | — | Contracting |
| Revenue growth | — | Modest |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | — | Mixed |
| 52-week position | The bottom quarter | The top quarter |
Full single-stock breakdowns: PBLS fair value analysis · PSNL fair value analysis